4ANL

Structure of G1269A Mutant Anaplastic Lymphoma Kinase

Summary for 4ANL

• Entry DOI: 10.2210/pdb4anl/pdb
• Related: 4ANQ 4ANS 4AOI
• Descriptor: ALK TYROSINE KINASE RECEPTOR (2 entities in total)
• Functional Keywords: transferase, crizotinib
• Biological source: HOMO SAPIENS (HUMAN)
• Total number of polymer chains: 1
• Total formula weight: 38610.15

Authors

McTigue, M.,Deng, Y.,Liu, W.,Brooun, A. (deposition date: 2012-03-20, release date: 2013-03-27, Last modification date: 2023-12-20)

• Primary citation: Huang, Q.,Johnson, T.W.,Bailey, S.,Brooun, A.,Bunker, K.D.,Burke, B.J.,Collins, M.R.,Cook, A.S.,Cui, J.J.,Dack, K.N.,Deal, J.G.,Deng, Y.,Dinh, D.,Engstrom, L.D.,He, M.,Hoffman, J.,Hoffman, R.L.,Johnson, P.S.,Kania, R.S.,Lam, H.,Lam, J.L.,Le, P.T.,Li, Q.,Lingardo, L.,Liu, W.,Lu, M.W.,Mctigue, M.,Palmer, C.L.,Richardson, P.F.,Sach, N.W.,Shen, H.,Smeal, T.,Smith, G.L.,Stewart, A.E.,Timofeevski, S.,Tsaparikos, K.,Wang, H.,Zhu, H.,Zhu, J.,Zou, H.Y.,Edwards, M.P.; Design of Potent and Selective Inhibitors to Overcome Clinical Anaplastic Lymphoma Kinase Mutations Resistant to Crizotinib.; J.Med.Chem., 57:1170-, 2014; PubMed: 24432909; DOI: 10.1021/JM401805H

Experimental method

X-RAY DIFFRACTION (1.7 Å)